One stock that might be an intriguing choice for investors right now is Eiger BioPharmaceuticals, Inc. EIGR. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 49 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Eiger BioPharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
Eiger BioPharmaceuticals, Inc. Price and Consensus
Eiger BioPharmaceuticals, Inc. price-consensus-chart | Eiger BioPharmaceuticals, Inc. Quote
In fact, over the past month, current quarter estimates have narrowed from a loss of 78 cents per share to a loss of 75 cents per share, while current year estimates have narrowed from a loss of $1.73 per share to a loss of $1.65 per share. This has helped EIGR to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So, if you are looking for a decent pick in a strong industry, consider Eiger BioPharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eiger BioPharmaceuticals, Inc. (EIGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.